Chenivesse X, Huby T, Wickins J, Chapman J, Thillet J
Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 321, "Lipoprotéines et Athérogénèse", Hôpital de la Pitié, PARIS, France.
Biochemistry. 1998 May 19;37(20):7213-23. doi: 10.1021/bi9721546.
Insight into the structural features of human lipoprotein(a) [Lp(a)] which underlie its functional implication in fibrinolysis may be gained from comparative studies of apo(a). Indeed, cloning of rhesus monkey apo(a) has shown that a Trp72 --> Arg mutation in the lysine-binding site (LBS) of KIV-10 leads to loss of lysine-binding properties of the rhesus Lp(a) particle. Consequently, comparative studies of apo(a) sequences in different Old World monkey species should further our understanding of the molecular role of Lp(a) in the fibrinolytic process. In contrast to other Old World monkeys, including rhesus monkey, cynomolgus, and baboon, the chimpanzee exhibits an elevated level of Lp(a) and a distinct isoform distribution as compared to humans [Doucet et al. J. Lipid Res. (1994) 35, 263-270]. Clearly then, the chimpanzee is an interesting animal model for study of the structure, function, and potential pathophysiological roles of Lp(a). We have cloned and sequenced the region of chimpanzee apo(a) cDNA spanning KIV-3 to the stop codon. The global organization of this region is similar to that of human apo(a) with the presence of KV, which is absent in rhesus monkey apo(a). Nucleotide sequence comparison indicates a variation of 1.4% between chimpanzee and man and 5.1% between chimpanzee and rhesus monkey. The differences concerned single base changes. An Asp57 --> Asn mutation was detected in KIV-10; this residue is critical to the LBS of KIV-10 in human apo(a). To verify that the Asp57 --> Asn substitution was specific to apo(a), we have also cloned the cDNA-encoding plasminogen, which exhibited an Asp at the corresponding position in kringle IV. Using an in vitro binding assay, we have demonstrated that chimpanzee Lp(a) exhibits poor lysine-specific interaction with both intact and plasmin-degraded fibrin as compared to its human counterpart. We propose that the Asn57 substitution in KIV-10 of chimpanzee apo(a) is responsible for this property. Chimpanzee Lp(a) therefore represents an appropriate particle with which to explore the potential effects of Lp(a) on the fibrinolytic system, such as the inhibition of plasminogen activation or inhibition of t-PA activity.
通过对载脂蛋白(a) [Lp(a)]的比较研究,或许能够深入了解其在纤维蛋白溶解中的功能所基于的结构特征。事实上,恒河猴载脂蛋白(a)的克隆表明,KIV - 10赖氨酸结合位点(LBS)中的Trp72→Arg突变导致恒河猴Lp(a)颗粒丧失赖氨酸结合特性。因此,对不同旧世界猴物种中载脂蛋白(a)序列的比较研究应能增进我们对Lp(a)在纤维蛋白溶解过程中分子作用的理解。与其他旧世界猴,包括恒河猴、食蟹猴和狒狒不同,黑猩猩的Lp(a)水平升高,且与人类相比具有独特的异构体分布[杜塞特等人,《脂质研究杂志》(1994年)35卷,263 - 270页]。显然,黑猩猩是研究Lp(a)的结构、功能及潜在病理生理作用的有趣动物模型。我们已克隆并测序了黑猩猩载脂蛋白(a) cDNA中从KIV - 3到终止密码子的区域。该区域的整体组织与人类载脂蛋白(a)相似,存在KV,而恒河猴载脂蛋白(a)中不存在。核苷酸序列比较表明,黑猩猩与人之间的差异为1.4%,与恒河猴之间的差异为5.1%。差异涉及单个碱基变化。在KIV - 10中检测到Asp57→Asn突变;该残基对人类载脂蛋白(a)中KIV - 10的LBS至关重要。为验证Asp57→Asn替代是否为载脂蛋白(a)所特有,我们还克隆了编码纤溶酶原的cDNA,其在kringle IV的相应位置显示为Asp。使用体外结合试验,我们已证明,与人类对应物相比,黑猩猩Lp(a)与完整和纤溶酶降解的纤维蛋白的赖氨酸特异性相互作用较差。我们认为,黑猩猩载脂蛋白(a)的KIV - 10中的Asn57替代是造成此特性的原因。因此,黑猩猩Lp(a)是探索Lp(a)对纤维蛋白溶解系统潜在影响(如抑制纤溶酶原激活或抑制t - PA活性)的合适颗粒。